Pfizer (PFE) FDA Approves XALKORI for Lung Cancer

Thank you for joining us. I am your host Yohemy Auerbach at CRWE Newswire Stocks to watch. Pfizer Incorporated - symbol PFE - reported that the U.S. Food and Drug Administration has approved its XALKORI. the first-ever therapy targeting anaplastic lymphoma kinase, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test. lung cancer is responsible for more deaths in both men and women each year worldwide than any other type of cancer. Pfizer’s XALKORI is an advance in the treatment of this devastating illness, providing a new therapeutic option for a subset of patients with the disease. Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Thank you for tuning in, have a great day. For CRWE Newswire, Stocks to watch, I’m Yohemy Auerbach.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

1. By: karmastock
2. Categories News & Events
3. Views 28
4. Added :28-Aug-11
   Report This Video